Login to Your Account



Includes $600M In Committed Payments

MorphoSys Nails Down Potential $1B-Plus Novartis Antibody Deal

By Jennifer Boggs


Tuesday, December 4, 2007
German biotech MorphoSys Inc., the latest firm to benefit from big pharma's burgeoning interest in antibodies, signed its, by far, largest deal to date, partnering with Novartis AG in a 10-year discovery and development alliance that could be worth more than $1 billion. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription